Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis
eLife · 27.08.2025 · 13
DOI: 10.7554/elife.95880 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 27.08.2025. Verfasst von Katsuyuki Nishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Stem Cell Biology and Medical Innovation (HSCBMI), Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Hematopoiesis, Myeloid Cells, Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, RIKEN.
Abstract (Originalsprache)
Myeloid-biased hematopoiesis is a well-known age-related alteration. Several possibilities, including myeloid-biased hematopoietic stem cell (HSC) clones, may explain this. However, the precise mechanisms remain controversial. Utilizing the Hoxb5 reporter system to prospectively isolate long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs), we found that young and aged LT-HSCs co-transplanted into the same recipients demonstrated nearly equivalent myeloid lineage output, contrary to the theory of myeloid-biased HSC clones. Transcriptomics indicated no significant myeloid gene enrichment in aged LT-HSCs compared to their young counterparts. Instead, transplanting reconstituted young HSCs with the ratio of LT/ST-HSCs seen in aged mice can significantly skew the lineage output to myeloid cells. In addition, while the niche environment in the bone marrow minimally affects myeloid-biased hematopoiesis, aged thymi and spleens substantially hinder lymphoid hematopoiesis, resulting in further myeloid domination. Thus, we demonstrate that myeloid-biased hematopoiesis in aged mice originates due to alteration of the ratio between LT-HSCs and ST-HSCs rather than in heterogeneous HSC clones with various cell fates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematopoietic Stem Cell Biology and Medical Innovation (HSCBMI), Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
- RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
- Weill Cornell, Rockefeller, Sloan-Kettering, Tri-Institutional MD-PhD Program, New York, United States.
- Institute of Laboratory Animals, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Pediatrics, Kobe University Graduate School of Medicine, Kyoto, Japan.
- Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Katsuyuki Nishi, Nobuyuki Yamamoto, Akifumi Takaori-Kondo, Masanori Miyanishi
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- RIKEN
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Life Science Foundation of Japan
- Takeda Science Foundation
- Astellas Foundation for Research on Metabolic Disorders
Zitieren
APA
Nishi, K., Sakamaki, T., Nagasaka, A., Kao, K. S., Sadaoka, K., Asano, M., Yamamoto, N., Takaori-Kondo, A., & Miyanishi, M. (2025). Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis. eLife, 13. https://doi.org/10.7554/elife.95880
Vancouver
Nishi K, Sakamaki T, Nagasaka A, Kao KS, Sadaoka K, Asano M, et al. Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis. eLife. 2025;13. doi:10.7554/elife.95880
BibTeX
@article{Nishi2025,
author = {Nishi, Katsuyuki and Sakamaki, Taro and Nagasaka, Akiomi and Kao, Kevin Shuolong and Sadaoka, Kay and Asano, Masahide and Yamamoto, Nobuyuki and Takaori-Kondo, Akifumi and Miyanishi, Masanori},
title = {Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis},
journal = {eLife},
year = {2025},
volume = {13},
doi = {10.7554/elife.95880}
}
EUVIMED